Robeva R, Heslan J M, Branellec A, Laurent J, Lagrue G
INSERM U139, Hôpital Henri Mondor, Creteil, France.
Clin Nephrol. 1988 Oct;30(4):211-5.
Idiopathic nephrotic syndrome (INS) is associated with a disorder of T-lymphocyte function, and an enhanced production of a vasoactive lymphokine, the vascular permeability factor (VPF). In an attempt to evaluate lymphocyte activation in various phases of INS, we measured beta 2-microglobulin (beta 2m) levels in lymphocyte culture supernatants (LCS). In 23 cases of untreated active INS, beta 2m levels in unstimulated LCS were significantly increased in comparison with those of 13 cases of untreated INS in complete remission (p less than 0.001), of 17 cases of active membranous nephropathy (p less than 0.01) and of 14 controls (p less than 0.001). In 13 patients treated with cyclosporine (Cs) (3-4.5 mg/kg/d) during 3 months, beta 2m levels were within the normal range. Although the beta 2m of 7 Cs patients without proteinuria was lower than 5 Cs patients with residual proteinuria, the difference was not statistically significant. In 15 prednisone(Pr)-treated INS patients, beta 2m levels were normalized. However their beta 2m levels were lower in 8 cases of complete remission than in 7 cases of persistent proteinuria (p less than 0.05). Concanavalin-A stimulation increased beta 2m amounts in all groups with a similar magnitude. In vitro addition of Cs (100 ng/ml) inhibited both beta 2m and VPF elevations observed in active INS. beta 2m level and VPF activity were significantly correlated (r = 0.54, p less than 0.01). High levels of beta 2m in LCS from INS are the consequence of an enhanced cellular synthesis and they are inhibited by Pr and Cs. Thus beta 2m increase in INS indeed reflects lymphocyte activation.
特发性肾病综合征(INS)与T淋巴细胞功能紊乱以及血管活性淋巴因子——血管通透性因子(VPF)的产生增加有关。为了评估INS各阶段的淋巴细胞活化情况,我们检测了淋巴细胞培养上清液(LCS)中的β2-微球蛋白(β2m)水平。23例未经治疗的活动性INS患者,未刺激的LCS中的β2m水平与13例完全缓解的未经治疗的INS患者(p<0.001)、17例活动性膜性肾病患者(p<0.01)及14例对照者(p<0.001)相比显著升高。13例接受环孢素(Cs)(3 - 4.5mg/kg/d)治疗3个月的患者,β2m水平在正常范围内。虽然7例无蛋白尿的Cs治疗患者的β2m低于5例有残余蛋白尿的Cs治疗患者,但差异无统计学意义。15例接受泼尼松(Pr)治疗的INS患者,β2m水平恢复正常。然而,8例完全缓解患者的β2m水平低于7例持续性蛋白尿患者(p<0.05)。伴刀豆球蛋白A刺激使所有组的β2m量增加幅度相似。体外加入Cs(100ng/ml)可抑制活动性INS中观察到的β2m和VPF升高。β2m水平与VPF活性显著相关(r = 0.54,p<0.01)。INS患者LCS中高水平的β2m是细胞合成增强的结果,且被Pr和Cs抑制。因此,INS中β2m升高确实反映了淋巴细胞活化。